Results of Two Studies of Pharmacokinetics, Safety, and Bioequivalence of Russian Generic Valsartan / Sacubitril Compared to the Original Valsartan / Sacubitril in Healthy Volunteers

Aim    To study the pharmacokinetics and safety and to prove the bioequivalence of Akrivario* (valsartan + sacubitril) film-coated tablets, at two dosages, 200 mg and 100 mg, compared to Uperio** (valsartan + sacubitril) film-coated tablets, at similar dosages, 200 mg and 100 mg (Studies 1 and 2, respectively), after oral administration to fasted healthy volunteers.
Material and methods    Two four-period, crossover-design bioequivalence studies were conducted. In each study, fasted healthy volunteers (Study 1: n=60; Study 2: n=59) received a single dose of the drugs. The interval between drug administrations was 7 days. Analyte concentrations in blood samples were measured by validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Pharmacokinetic parameters were determined for both valsartan and sacubitril in both studies.
Results    The 90% confidence intervals for the Ln-transformed ratios of all assessed pharmacokinetic parameters (Cmax and AUC0-t for valsartan and sacubitril) were in the range of 80-125%. Both study drugs were well tolerated; all adverse events (AEs) were mild and did not require additional therapy. No clinically significant AEs were observed during the study.
Conclusion: The study demonstrated bioequivalence of Akrivario (valsartan + sacubitril) to the reference drug Uperio (valsartan + sacubitril).

1. Vasan RS, Enserro DM, Beiser AS, Xanthakis V. Lifetime Risk of Heart Failure Among Participants in the Framingham Study. Journal of the American College of Cardiology. 2022;79(3):250–63. DOI: 10.1016/j.jacc.2021.10.043

2. Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K et al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. Journal of Cardiac Failure. 2023;29(10):1412–51. DOI: 10.1016/j.cardfail.2023.07.006

3. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCHCHF study. Kardiologiia. 2021;61(4):4–14. DOI: 10.18087/cardio.2021.4.n1628

4. Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survi val of patients with chronic heart failure in the community: a systematic review and meta‐analysis. European Journal of Heart Failure. 2019;21(11):1306–25. DOI: 10.1002/ejhf.1594

5. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation ‘PRIORITET-CHF’: initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):93–103. DOI: 10.15829/1560-4071-2023-5593

6. Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024;403(10440):2100–32. DOI: 10.1016/S0140-6736(24)00367-2

7. Andersen MB, Simonsen U, Wehland M, Pietsch J, Grimm D. LCZ696 (Valsartan/Sacubitril) – A Possible New Treatment for Hypertension and Heart Failure. Basic & Clinical Pharmacology & Toxicology. 2016;118(1):14–22. DOI: 10.1111/bcpt.12453

8. Butt JH, Dewan P, Jhund PS, Anand IS, Atar D, Ge J et al. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology. 2022;80(12):1130–43. DOI: 10.1016/j.jacc.2022.06.037

9. Lou Y, Yu Y, Liu J, Huang J. Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials. Frontiers in Public Health. 2022;10:959139. DOI: 10.3389/fpubh.2022.959139

10. Oshchepkova E.V. Experience of sacubitril/valsartan therapy in hypertension. Cardiovascular Therapy and Prevention. 2023;22(7):83–97. DOI: 10.15829/1728-8800-2023-3636

11. Galyavich A.S., Tereshchenko S.N., Uskach T.M., Ageev F.T., Aronov D.M., Arutyunov G.P. et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):251–349. DOI: 10.15829/1560-4071-2024-6162

12. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):230– 329. DOI: 10.15829/1560-4071-2024-6117

13. Ministry of Health of the Russian Federation. Guidelines for the examination of medicines. Volume 1. - M.: Gryph and Co; 2014. - 328p. ISBN 978-5-8125-1858-5

14. Decision of the Council of the Eurasian Economic Commission dated dated November 3, 2016, No. 85 ‘On Approval of the Rules for Conducting Bioequivalence Studies of Medicinal Products within the Eurasian Economic Union’. Av. at: https://www.alta.ru/tamdoc/16sr0085/?ysclid=mgqhiwqmdb356550488.